Primary biliary cirrhosis and autoimmune cholangitis

Liver Immunology: Principles and Practice

Volumn , Issue , 2007, Pages 235-247

  Selmi, Carlo ^a,b   Lleo, Ana ^a   Invernizzi, Pietro ^a   Gershwin, M Eric ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80054763620     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59745-518-3_19     Document Type: Chapter

References (67)

1. Ahrens EH Jr, Payne MA, Kunkel HG, Eisenmenger WJ, Blondheim SH. Primary biliary cirrhosis. Medicine (Balti) 1950; 29:299-364
2. Sherlock S. Primary biliary cirrhosis (chronic intrahepatic obstructive jaundice). Gastroenterology 1959; 37:574-586
3. Walker JG, Doniach D, Roitt IM, Sherlock S. Serological tests in diagnosis of primary biliary cirrhosis. Lancet 1965; 39:827-831
4. Gershwin ME, Mackay IR, Sturgess A, Coppel RL. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol 1987; 138: 3525-3531
5. Metcalf JV, Bhopal RS, Gray J, Howel D, James OF. Incidence and prevalence of primary biliary cirrhosis in the city of Newcastle upon Tyne, England. Int J Epidemiol 1997; 26:830-836
6. Invernizzi P, Crosignani A, Battezzati PM, et al. Comparison of the clinical features and clinical course of antimitochondrial antibodypositive and -negative primary biliary cirrhosis. Hepatology 1997; 25:1090-1095
7. Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 2000; 31:1005-1013
8. Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005; 42:481-489
9. Inoue K, Hirohara J, Nakano T, et al. Prediction of prognosis of primary biliary cirrhosis in Japan. Liver 1995; 15:70-77
10. Navasa M, Pares A, Bruguera M, Caballeria J, Bosch J, Rodes J. Portal hypertension in primary biliary cirrhosis. Relationship with histological features. J Hepatol 1987; 5:292-298
11. Forton DM, Patel N, Prince M, et al. Fatigue and primary biliary cirrhosis: Association of globus pallidus magnetisation transfer ratio measurements with fatigue severity and blood manganese levels. Gut 2004; 53:587-592
12. Bergasa NV, Mehlman JK, Jones EA. Pruritus and fatigue in primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol 2000; 14:643-655
13. Terg R, Coronel E, Sorda J, Munoz AE, Findor J. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002; 37:717-722
14. Lindor KD, Jorgensen RA, Therneau TM, Malinchoc M, Dickson ER. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc 1997; 72:1137-1140
15. Zein CO, Jorgensen RA, Clarke B, et al. Alendronate improves bone mineral density in primary biliary cirrhosis: A randomized placebocontrolled trial. Hepatology 2005; 42:762-771
16. Allocca M, Crosignani A, Gritti A, et al. Hypercholesterolaemia is not associated with early atherosclerotic lesions in primary biliary cirrhosis. Gut 2006; 55:1795-1800
17. Lanspa SJ, Chan AT, Bell JS 3rd, Go VL, Dickson ER, DiMagno EP. Pathogenesis of steatorrhea in primary biliary cirrhosis. Hepatology 1985; 5:837-842
18. Phillips JR, Angulo P, Petterson T, Lindor KD. Fat-soluble vitamin levels in patients with primary biliary cirrhosis. Am J Gastroenterol 2001; 96:2745-2750
19. Gershwin ME, Selmi C, Worman HJ, et al. Risk factors and comorbidities in primary biliary cirrhosis: A controlled interview-based study of 1032 patients. Hepatology 2005; 42:1194-1202
20. Findor J, He XS, Sord J, Terg R, Gershwin ME. Primary biliary cirrhosis and hepatocellular carcinoma. Autoimmun Rev 2002; 1:220-225
21. Howel D, Fischbacher CM, Bhopal RS, Gray J, Metcalf JV, James OF. An exploratory population-based case-control study of primary biliary cirrhosis. Hepatology 2000; 31:1055-1060
22. Springer J, Cauch-Dudek K, O'Rourke K, Wanless IR, Heathcote EJ. Asymptomatic primary biliary cirrhosis: A study of its natural history and prognosis. Am J Gastroenterol 1999; 94:47-53
23. Prince MI, Chetwynd A, Craig WL, Metcalf JV, James OF. Asymptomatic primary biliary cirrhosis: Clinical features, prognosis, and symptom progression in a large population based cohort. Gut 2004; 53:865-870
24. Grambsch PM, Dickson ER, Kaplan M, LeSage G, Fleming TR, Langworthy AL. Extramural cross-validation of the Mayo primary biliary cirrhosis survival model establishes its generalizability. Hepatology 1989; 10:846-850
25. Wesierska-Gadek J, Penner E, Battezzati PM, et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 2006; 43:1135-1144
26. Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978; 379:103-112
27. Tsuneyama K, Harada K, Kono N, et al. Scavenger cells with gram-positive bacterial lipoteichoic acid infiltrate around the damaged interlobular bile ducts of primary biliary cirrhosis. J Hepatol 2001; 35:156-163
28. Harada K, Ozaki S, Sudo Y, Tsuneyama K, Ohta H, Nakanuma Y. Osteopontin is involved in the formation of epithelioid granuloma and bile duct injury in primary biliary cirrhosis. Pathol Int 2003; 53:8-17
29. Goldstein NS, Soman A, Gordon SC. Portal tract eosinophils and hepatocyte cytokeratin 7 immunoreactivity helps distinguish early-stage, mildly active primary biliary cirrhosis and autoimmune hepatitis. Am J Clin Pathol 2001; 116:846-853
30. Neuberger J. Eosinophils and primary biliary cirrhosis-stoking the fire? Hepatology 1999; 30:335-337
31. Selmi C, Invernizzi P, Zuin M, Podda M, Gershwin ME. Genetics and geoepidemiology of primary biliary cirrhosis: Following the footprints to disease etiology. Semin Liver Dis 2005; 25:265-280
32. Kim WR, Lindor KD, Locke GR 3rd, et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 2000; 119:1631-1636
33. Gershwin ME, Ansari AA, Mackay IR, et al. Primary biliary cirrhosis: An orchestrated immune response against epithelial cells. Immunol Rev 2000; 174:210-225
34. Ishibashi H, Nakamura M, Shimoda S, Gershwin ME. T cell immunity and primary biliary cirrhosis. Autoimmun Rev 2003; 2:19-24
35. Bogdanos DP, Baum H, Vergani D. Antimitochondrial and other autoantibodies. Clin Liver Dis 2003; 7:759-777, vi.
36. Miyakawa H, Tanaka A, Kikuchi K, et al. Detection of antimitochondrial autoantibodies in immunofluorescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens. Hepatology 2001; 34:243-248
37. Invernizzi P, Selmi C, Ranftler C, Podda M, Wesierska-Gadek J. Antinuclear antibodies in primary biliary cirrhosis. Semin Liver Dis 2005; 25:298-310
38. Van de Water J, Ansari AA, Surh CD, et al. Evidence for the targeting by 2-oxodehydrogenase enzymes in the T cell response of primary biliary cirrhosis. J Immunol 1991; 146:89-94
39. Selmi C, Mayo MJ, Bach N, et al. Primary biliary cirrhosis in monozygotic and dizygotic twins: Genetics, epigenetics, and environment. Gastroenterology 2004;127:485-492
40. Jones DE, Donaldson PT. Genetic factors in the pathogenesis of primary biliary cirrhosis. Clin Liver Dis 2003; 7:841-864
41. Invernizzi P, Selmi C, Mackay IR, Podda M, Gershwin ME. From bases to basis: Linking genetics to causation in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2005; 3:401-410
42. Invernizzi P, De Andreis C, Sirchia SM, et al. Blood fetal microchimerism in primary biliary cirrhosis. Clin Exp Immunol 2000; 122:418-422
43. Invernizzi P, Miozzo M, Battezzati PM, et al. Frequency of monosomy X in women with primary biliary cirrhosis. Lancet 2004; 363:533-535
44. Van de Water J, Ishibashi H, Coppel RL, Gershwin ME. Molecular mimicry and primary biliary cirrhosis: Premises not promises. Hepatology 2001; 33:771-775
45. Selmi C, Gershwin ME. Bacteria and human autoimmunity: The case of primary biliary cirrhosis. Curr Opin Rheumatol 2004; 16:406-410
46. Muratori P, Muratori L, Guidi M, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. Clin Exp Immunol 2003; 132:473-476
47. Abdulkarim AS, Petrovic LM, Kim WR, Angulo P, Lloyd RV, Lindor KD. Primary biliary cirrhosis: An infectious disease caused by Chlamydia pneumoniae? J Hepatol 2004; 40:380-384
48. Leung PS, Park O, Matsumura S, Ansari AA, Coppel RL, Gershwin ME. Is there a relation between Chlamydia infection and primary biliary cirrhosis? Clin Dev Immunol 2003; 10:227-233
49. Selmi C, Balkwill DL, Invernizzi P, et al. Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology 2003; 38:1250-1257
50. Selmi C, Ross SR, Ansari AA, et al. Lack of immunological or molecular evidence for a role of mouse mammary tumor retrovirus in primary biliary cirrhosis. Gastroenterology 2004; 127: 493-495
51. Long SA, Quan C, Van de Water J, et al. Immunoreactivity of organic mimeotopes of the E2 component of pyruvate dehydrogenase: Connecting xenobiotics with primary biliary cirrhosis. J Immunol 2001; 167:2956-2963
52. Leung PS, Quan C, Park O, et al. Immunization with a xenobiotic 6-bromohexanoate bovine serum albumin conjugate induces antimitochondrial antibodies. J Immunol 2003; 170:5326-5332
53. Shimoda S, Nakamura M, Ishibashi H, et al. Molecular mimicry of mitochondrial and nuclear autoantigens in primary biliary cirrhosis. Gastroenterology 2003; 124:1915-1925
54. Irie J, Wu Y, Wicker LS, et al. NOD.c3c4 congenic mice develop autoimmune biliary disease that serologically and pathogenetically models human primary biliary cirrhosis. J Exp Med 2006; 203:1209-1219
55. Padgett KA, Selmi C, Kenny TP, et al. Phylogenetic and immunological definition of four lipoylated proteins from Novosphingobium aromaticivorans, implications for primary biliary cirrhosis. J Autoimmun 2005; 24:209-219
56. Lan RY, Cheng C, Lian ZX, et al. Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis. Hepatology 2006; 43:729-737
57. Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2002:CD000551
58. Leuschner M, Dietrich CF, You T, et al. Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment. Gut 2000; 46:121-126
59. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology 2006; 130:715-720
60. Itakura J, Izumi N, Nishimura Y, et al. Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis. Hepatol Res 2004; 29:216-222
61. Talwalkar JA, Angulo P, Keach JC, Petz JL, Jorgensen RA, Lindor KD. Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. J Clin Gastroenterol 2005; 39:168-171
62. Combes B, Emerson SS, Flye NL, et al. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology 2005; 42:1184-1193
63. Rautiainen H, Karkkainen P, Karvonen AL, et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: A three-year randomized trial. Hepatology 2005; 41: 747-752
64. Reddy A, Prince M, James OF, Jain S, Bassendine MF. Tamoxifen: A novel treatment for primary biliary cirrhosis? Liver Int 2004; 24:194-197
65. Invernizzi P, Alvaro D, Crosignani A, Gaudio E, Podda M. Tamoxifen in treatment of primary biliary cirrhosis. Hepatology 2004; 39:1175-1176
66. Heathcote J. Autoimmune cholangitis. Gut 1997; 40:440-442
67. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology 2000; 31:1231-1238